ABT-SLV176

Phase 3Withdrawn
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadism

Conditions

Hypogonadism, Testosterone Deficiency

Trial Timeline

Mar 1, 2014 โ†’ Jun 1, 2015

About ABT-SLV176

ABT-SLV176 is a phase 3 stage product being developed by AbbVie for Hypogonadism. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02082197. Target conditions include Hypogonadism, Testosterone Deficiency.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02082197Phase 3Withdrawn